Oxigene’s pancreatic cancer treatments granted orphan drug status in Europe

Oxigene Inc. said its treatment for pancreatic cancer, CA4P, was granted orphan drug status by the European Commission. That gives the company 10 years of marketing exclusivity in European Union member countries if the product is approved. Earlier this year, CA4P was granted the orphan drug designation for neuroendocrine tumors (NETs) in the U.S. “This designation represents another successful step as we execute on our strategy of bolstering the proprietary position of CA4P in the potential indications in which we are most interested,” said Chief Executive William Schwieterman. “Separately, we continue to expect final data from our phase 2a clinical trial of CA4P in NETs to be available later in 2016.” The stock has slumped 11% so far this year and 53% over the last 12 months. The S&P 500 has slipped 0.4% year to date and 1.1% the past year.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Pineapple Express adds Hustler’s Larry Flynt as an investor

Pineapple Express Inc. said Larry Flynt, the founder of publisher of Hustler Magazine, has bought 100,000 shares of the cannabis business developer for $100,000. Flynt will be restricted from trading the shares for a defined period of time. “We are fortunate to have such an amazing investor by our side,” said Chief Executive Matthew Feinstein. “Knowing that Mr. Flynt has made an investment in our company provides impetus for everyone at headquarters to surpass expectations and deliver excellent results.” The company’s common stock, which trades on the OTC Pink exchange, closed Thursday at $10.10. It has rocketed six fold since closing at $1.68 on Dec. 31.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Hologic, Centene tick higher on S&P 500 inclusion

Shares of Hologic Inc. and Centene Corp. ticked higher in the extended session Thursday after S&P Dow Jones Indices said the companies will join the S&P 500 index . Hologic shares rose 2% to $35.04, and Centene shares advanced 1.5% to $64.71 after hours. Medical-device maker Hologic replaces Pepco Holdings Inc., which was acquired by Exelon Corp. , and health insurer Centene replaces Ensco PLC . The changes take effect on Tuesday.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News